<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="348f148b-3e1a-fe2d-e063-6294a90a9b22"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METOCLOPRAMIDE TABLETS safely and effectively. See full prescribing information for METOCLOPRAMIDE TABLETS.
 <br/>
      <br/>
Metoclopramide tablets, for oral use
 <br/>
Initial U.S. Approval: 1979
</title>
   <effectiveTime value="20250507"/>
   <setId root="b16ad17c-eeea-407e-91e4-36506e9aa698"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="079391286"/>
            <name>ScieGen Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="079674526"/>
                  <name>AiPing Pharmaceutical, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080225262"/>
                        <name>A&amp;Z Pharmaceutical Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50228-232" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50228-233" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="348f1683-0a95-1366-e063-6294a90ab4b7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250507"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50228-232" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metoclopramide</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metoclopramide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="W1792A2RVD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METOCLOPRAMIDE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="L4YEB44I46" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METOCLOPRAMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50228-232-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250212"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50228-232-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250212"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA072215" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250212"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">345</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50228-233" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metoclopramide</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metoclopramide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="W1792A2RVD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METOCLOPRAMIDE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="L4YEB44I46" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METOCLOPRAMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50228-233-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250212"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50228-233-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250212"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50228-233-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250212"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA072215" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250212"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">346</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID543">
               <id root="348f148b-3e1b-fe2d-e063-6294a90a9b22"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: TARDIVE DYSKINESIA</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Metoclopramide tablets can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage
   
    <content styleCode="italics">[see Warnings and Precautions (
    
     <linkHtml href="#ID601">5.1</linkHtml>)]
   
    </content>.
  
   </content>
                     </item>
                     <item>
                        <content styleCode="bold">Discontinue metoclopramide tablets in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide tablets is stopped
   
    <content styleCode="italics">[see Warnings and Precautions (
    
     <linkHtml href="#ID601">5.1</linkHtml>)]
   
    </content>.
  
   </content>
                     </item>
                     <item>
                        <content styleCode="bold">Avoid treatment with metoclopramide tablets for longer than 12 weeks because of the increased risk of developing TD with longer-term use
   
    <content styleCode="italics">[see Warnings and Precautions (
    
     <linkHtml href="#ID601">5.1</linkHtml>) and Dosage and Administration (
    
     <linkHtml href="#ID589">2.2</linkHtml>,
    
     <linkHtml href="#ID592">2.3</linkHtml>)]
   
    </content>.
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID545">
                           <content styleCode="bold">WARNING: TARDIVE DYSKINESIA</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph/>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Metoclopramide tablets can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage (
   
      <linkHtml href="#ID601">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Discontinue Metoclopramide tablets in patients who develop signs or symptoms of TD (
   
      <linkHtml href="#ID601">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Avoid treatment with Metoclopramide tablets for longer than 12 weeks because of the risk of developing TD with longer-term use (
   
      <linkHtml href="#ID601">5.1</linkHtml>,
   
      <linkHtml href="#ID587">2.1</linkHtml>,
   
      <linkHtml href="#ID589">2.2</linkHtml>,
   
      <linkHtml href="#ID592">2.3</linkHtml>)
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID551">
               <id root="348f148b-3e1c-fe2d-e063-6294a90a9b22"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID553">Metoclopramide tablets are indicated for the:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. (
  
     <linkHtml href="#ID551">1</linkHtml>)
 
    </item>
                           <item>Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. (
  
     <linkHtml href="#ID551">1</linkHtml>)
 
    </item>
                        </list>
                        <paragraph ID="ID555">
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. (
 
    <linkHtml href="#ID551">1</linkHtml>,
 
    <linkHtml href="#ID635">8.4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID581">
                     <id root="348f148b-3e1d-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID582">Metoclopramide tablets are indicated for the:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy.</item>
                           <item>Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.</item>
                        </list>
                        <paragraph ID="ID584">
                           <content styleCode="underline">Limitations of Use</content>:

 </paragraph>
                        <paragraph>Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID635">8.4</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID556">
               <id root="348f148b-3e1e-fe2d-e063-6294a90a9b22"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID558">
                           <content styleCode="underline">Gastroesophageal Reflux</content>(
 
    <linkHtml href="#ID589">2.2</linkHtml>)

   </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer metoclopramide tablets continuously or intermittently:
  
     <list listType="unordered" styleCode="Circle">
                                 <item>Continuous: Administer 10 to 15 mg, 30 minutes before each meal and at bedtime (maximum of 60 mg per day) for 4 to 12 weeks.</item>
                                 <item>Intermittent: Single doses up to 20 mg prior to provoking situation.</item>
                              </list>
                           </item>
                        </list>
                        <paragraph ID="ID560">
                           <content styleCode="underline">Acute and Recurrent Diabetic Gastroparesis</content>(
 
    <linkHtml href="#ID592">2.3</linkHtml>)

   </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer 10 mg, 30 minutes before each meal and at bedtime (maximum of 40 mg per day) for 2 to 8 weeks.</item>
                        </list>
                        <paragraph ID="ID562">
                           <content styleCode="underline">Dosage Adjustment in Specific Populations</content>(
 
    <linkHtml href="#ID589">2.2</linkHtml>,
 
    <linkHtml href="#ID592">2.3</linkHtml>)

   </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>For gastroesophageal reflux and acute and recurrent diabetic gastroparesis, see Full Prescribing Information for recommended dosage reductions for elderly patients, in patients with moderate or severe hepatic or renal impairment, and cytochrome P450 2D6 (CYP2D6) poor metabolizers.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID587">
                     <id root="348f148b-3e1f-fe2d-e063-6294a90a9b22"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <paragraph ID="ID588">Avoid treatment with metoclopramide tablets for longer than 12 weeks because of the increased risk of developing TD with longer-term use
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="ID589">
                     <id root="348f148b-3e20-fe2d-e063-6294a90a9b22"/>
                     <title>2.2 Dosage for Gastroesophageal Reflux</title>
                     <text>
                        <paragraph ID="ID705">Metoclopramide tablets may be administered continuously or intermittently in patients with symptomatic gastroesophageal reflux who fail to respond to conventional therapy:</paragraph>
                        <paragraph>
                           <content styleCode="underline">Continuous Dosing</content>
                        </paragraph>
                        <paragraph>The recommended adult dosage of metoclopramide tablets is 10 to 15 mg four times daily for 4 to 12 weeks. The treatment duration is determined by endoscopic response. Administer the dosage thirty minutes before each meal and at bedtime. The maximum recommended daily dosage is 60 mg.</paragraph>
                        <paragraph ID="ID706">Table 1 displays the recommended daily dosage and maximum daily dosage for adults and dosage adjustments for patients with moderate or severe hepatic impairment (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute, in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with strong CYP2D6 inhibitors.</paragraph>
                        <paragraph ID="ID707">
                           <content styleCode="underline">Intermittent Dosing</content>
                        </paragraph>
                        <paragraph>If symptoms only occur intermittently or at specific times of the day, administer metoclopramide tablets in single dose up to 20 mg prior to the provoking situation. Consider dosage reductions for the populations and situations in Table 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Recommended Metoclopramide Tablets Dosage in Patients with Gastroesophageal Reflux</content>
                        </paragraph>
                        <table ID="ID716" width="666">
                           <col width="300"/>
                           <col width="210"/>
                           <col width="156"/>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3" align="left">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup>Elderly patients may be more sensitive to the therapeutic or adverse effects of metoclopramide tablets; therefore, consider a lower starting dosage of 5 mg four times daily with titration to the recommended adult dosage of 10 to 15 mg four times daily based upon response and tolerability.
    
     </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Botrule Rrule Toprule">
                                    <content styleCode="bold">Recommended Dosage</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule">
                                    <content styleCode="bold">Maximum</content>
                                    <br/>
                                    <content styleCode="bold">Recommended</content>
                                    <br/>
                                    <content styleCode="bold">Daily Dosage</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Adult patients</td>
                                 <td rowspan="2" align="left" styleCode="Botrule Rrule">10 to 15 mg four times daily (thirty minutes before each meal and at bedtime)</td>
                                 <td rowspan="3" align="center" styleCode="Botrule Rrule">60 mg</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Mild hepatic impairment (Child-Pugh A)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Elderly patients
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID637">8.5</linkHtml>)]
    
     </content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">5 mg
    
     <sup>1</sup>four times daily (thirty minutes before each meal and at bedtime)
   
    </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Moderate or severe hepatic impairment (Child-Pugh B or C)
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID641">8.7</linkHtml>)]
    
     </content>
                                 </td>
                                 <td rowspan="4" align="left" styleCode="Botrule Rrule">5 mg four times daily (thirty minutes before each meal and at bedtime), or 10 mg taken three times daily</td>
                                 <td rowspan="4" align="center" styleCode="Botrule Rrule">30 mg</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">CYP2D6 poor metabolizers
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID645">8.9</linkHtml>)]
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Concomitant use with strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine)
    
     <content styleCode="italics">[see Drug Interactions (
     
      <linkHtml href="#ID625">7.1</linkHtml>)]
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Moderate or severe renal impairment (creatinine clearance less than or equal to 60 mL/minute)
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID639">8.6</linkHtml>)]
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Patients with End-Stage Renal Disease (ESRD) including those treated with hemodialysis and continuous ambulatory peritoneal dialysis
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID639">8.6</linkHtml>)]
    
     </content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">5 mg four times daily (thirty minutes before each meal and at bedtime) or 10 mg twice daily</td>
                                 <td align="center" styleCode="Botrule Rrule">20 mg</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="ID592">
                     <id root="348f148b-3e21-fe2d-e063-6294a90a9b22"/>
                     <title>2.3 Dosage for Acute and Recurrent Diabetic Gastroparesis</title>
                     <text>
                        <paragraph ID="ID708">The recommended adult dosage for the treatment of acute and recurrent diabetic gastroparesis is 10 mg four times daily for 2 to 8 weeks, depending on symptomatic response. Avoid metoclopramide tablets treatment for greater than 12 weeks
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>)]
 
  </content>. Administer the dosage thirty minutes before each meal and at bedtime. The maximum recommended daily dosage is 40 mg.

 </paragraph>
                        <paragraph ID="ID709">Table 2 displays the recommended daily dosage and maximum daily dosage for adults and dosage adjustments for patients with moderate or severe hepatic impairment (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute, in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with strong CYP2D6 inhibitors.</paragraph>
                        <paragraph ID="ID710">If patients with diabetic gastroparesis have severe nausea or vomiting and are unable to take oral metoclopramide tablets, consider starting therapy with metoclopramide injection given intramuscularly or intravenously for up to 10 days (see the prescribing information for metoclopramide injection). After patients are able to take oral therapy, switch to metoclopramide tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2. Recommended Metoclopramide Tablets Dosage in Patients with Acute and Recurrent Diabetic Gastroparesis</content>
                        </paragraph>
                        <table ID="ID717" width="666">
                           <col width="300"/>
                           <col width="210"/>
                           <col width="156"/>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="3" align="left">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup>Elderly patients may be more sensitive to the therapeutic or adverse effects of metoclopramide tablets; therefore, consider a lower dosage of 5 mg four times daily with titration to the recommended adult dosage of 10 mg four times daily based upon response and tolerability.
    
     </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Botrule Rrule Toprule">
                                    <content styleCode="bold">Recommended Dosage</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule">
                                    <content styleCode="bold">Maximum</content>
                                    <br/>
                                    <content styleCode="bold">Recommended</content>
                                    <br/>
                                    <content styleCode="bold">Daily Dosage</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Adult patients</td>
                                 <td rowspan="2" align="left" styleCode="Botrule Rrule">10 mg four times daily (thirty minutes before each meal and at bedtime)</td>
                                 <td rowspan="3" align="center" styleCode="Botrule Rrule">40 mg</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Mild hepatic impairment (Child-Pugh A)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Elderly patients
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID637">8.5</linkHtml>)]
    
     </content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">5 mg
    
     <sup>1</sup>four times daily (thirty minutes before each meal and at bedtime)
   
    </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Moderate or severe hepatic impairment (Child-Pugh B or C)
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID641">8.7</linkHtml>)]
    
     </content>
                                 </td>
                                 <td rowspan="4" align="left" styleCode="Botrule Rrule">5 mg four times daily (thirty minutes before each meal and at bedtime)</td>
                                 <td rowspan="4" align="center" styleCode="Botrule Rrule">20 mg</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">CYP2D6 poor metabolizers
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID645">8.9</linkHtml>)]
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Concomitant use with strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine)
    
     <content styleCode="italics">[see Drug Interactions (
     
      <linkHtml href="#ID625">7.1</linkHtml>)]
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Moderate or severe renal impairment (creatinine clearance less than or equal to 60 mL/minute)
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID639">8.6</linkHtml>)]
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">Patients with End-Stage Renal Disease (ESRD) including those treated with hemodialysis and continuous ambulatory peritoneal dialysis
    
     <content styleCode="italics">[see Use in Specific Populations (
     
      <linkHtml href="#ID639">8.6</linkHtml>)]
    
     </content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">5 mg twice daily</td>
                                 <td align="center" styleCode="Botrule Rrule">10 mg</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID564">
               <id root="348f148b-3e22-fe2d-e063-6294a90a9b22"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID566">Tablets: 5 mg and 10 mg metoclopramide (
 
    <linkHtml href="#ID564">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID595">
                     <id root="348f148b-3e23-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID596">Tablets:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>5 mg Metoclopramide tablets: white, round, biconvex tablets, debossed with “345” on one side and plain on the other side.</item>
                           <item>10 mg Metoclopramide tablets: white, round, biconvex tablets, debossed with “346” on one side and plain with a white bisect on the other side.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID567">
               <id root="348f148b-3e24-fe2d-e063-6294a90a9b22"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>History of TD or dystonic reaction to metoclopramide (
  
     <linkHtml href="#ID567">4</linkHtml>)
 
    </item>
                           <item>When stimulation of gastrointestinal motility might be dangerous (
  
     <linkHtml href="#ID567">4</linkHtml>)
 
    </item>
                           <item>Pheochromocytoma, catecholamine-releasing paragangliomas (
  
     <linkHtml href="#ID567">4</linkHtml>)
 
    </item>
                           <item>Epilepsy (
  
     <linkHtml href="#ID567">4</linkHtml>)
 
    </item>
                           <item>Hypersensitivity to metoclopramide (
  
     <linkHtml href="#ID567">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID598">
                     <id root="348f148b-3e25-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID599">Metoclopramide tablets are contraindicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID601">5.1</linkHtml>,
   
    <linkHtml href="#ID603">5.2</linkHtml>)]
  
   </content>.
 
  </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation).</item>
                           <item>In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide tablets may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID611">5.5</linkHtml>)]
  
   </content>.
 
  </item>
                           <item>In patients with epilepsy. Metoclopramide tablets may increase the frequency and severity of seizures
  
   <content styleCode="italics">[see Adverse Reactions (
   
    <linkHtml href="#ID573">6</linkHtml>)]
  
   </content>.
 
  </item>
                           <item>In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm
  
   <content styleCode="italics">[see Adverse Reactions (
   
    <linkHtml href="#ID573">6</linkHtml>)]
  
   </content>.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID570">
               <id root="348f148b-3e26-fe2d-e063-6294a90a9b22"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS)</content>: Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson's Disease. If symptoms occur, discontinue metoclopramide tablets and seek immediate medical attention. (
  
     <linkHtml href="#ID601">5.1</linkHtml>,
  
     <linkHtml href="#ID603">5.2</linkHtml>,
  
     <linkHtml href="#ID606">5.3</linkHtml>,
  
     <linkHtml href="#ID625">7.1</linkHtml>,
  
     <linkHtml href="#ID628">7.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Depression and suicidal ideation/suicide</content>: Avoid use. (
  
     <linkHtml href="#ID609">5.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID601">
                     <id root="348f148b-3e27-fe2d-e063-6294a90a9b22"/>
                     <title>5.1 Tardive Dyskinesia</title>
                     <text>
                        <paragraph ID="ID602">Metoclopramide can cause tardive dyskinesia (TD), a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities. Movements may be choreoathetotic in appearance. The risk of developing TD and the likelihood that TD will become irreversible increases with duration of treatment and total cumulative dosage. Additionally, the risk of developing TD is increased among the elderly, especially elderly women
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID637">8.5</linkHtml>)]
 
  </content>, and in patients with diabetes mellitus. Due to the risk of developing TD, avoid treatment with metoclopramide tablets for longer than 12 weeks and reduce the dosage in elderly patients
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>Discontinue metoclopramide tablets immediately in patients who develop signs and symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients TD may remit, partially or completely, within several weeks to months after metoclopramide tablets are withdrawn.</paragraph>
                        <paragraph>Metoclopramide tablets itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Metoclopramide tablets is contraindicated in patients with a history of TD
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#ID567">4</linkHtml>)].
 
  </content> Avoid metoclopramide tablets in patients receiving other drugs that are likely to cause TD (e.g., antipsychotics).

 </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID603">
                     <id root="348f148b-3e28-fe2d-e063-6294a90a9b22"/>
                     <title>5.2 Other Extrapyramidal Symptoms</title>
                     <text>
                        <paragraph ID="ID604">In addition to TD, metoclopramide may cause other extrapyramidal symptoms (EPS), parkinsonian symptoms, and motor restlessness. Advise patients to seek immediate medical attention if such symptoms occur and to discontinue metoclopramide tablets.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Extrapyramidal symptoms (EPS), such as acute dystonic reactions, occurred in patients treated with metoclopramide dosages of 30 mg to 40 mg daily. Such reactions occurred more frequently in adults less than 30 years of age and at higher than recommended dosages. EPS occurred more frequently in pediatric patients compared to adults (metoclopramide tablets are not approved for use in pediatric patients). Symptoms can occur in the first 24 to 48 hours after starting metoclopramide. Symptoms included involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus. Rarely, dystonic reactions were present as stridor and dyspnea, possibly due to laryngospasm. Diphenhydramine hydrochloride or benztropine mesylate may be used to treat these adverse reactions. Avoid metoclopramide tablets in patients receiving other drugs that can cause EPS (e.g., antipsychotics).</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Parkinsonian symptoms (bradykinesia, tremor, cogwheel rigidity, mask-like facies) have occurred after starting metoclopramide, more commonly within the first 6 months, but also after longer periods. Symptoms generally have subsided within 2 to 3 months after discontinuation of metoclopramide tablets. Avoid metoclopramide tablets in patients with Parkinson's disease and other patients being treated with antiparkinsonian drugs due to potential exacerbation of symptoms. Avoid treatment with metoclopramide tablets for more than 12 weeks
  
   <content styleCode="italics">[see Dosage and Administration (
   
    <linkHtml href="#ID589">2.2</linkHtml>,
   
    <linkHtml href="#ID592">2.3</linkHtml>), Warnings and Precautions (
   
    <linkHtml href="#ID601">5.1</linkHtml>)].
  
   </content>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Motor restlessness (akathisia) has developed and consisted of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, and foot tapping. If symptoms resolve, consider restarting at a lower dosage.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID606">
                     <id root="348f148b-3e29-fe2d-e063-6294a90a9b22"/>
                     <title>5.3 Neuroleptic Malignant Syndrome</title>
                     <text>
                        <paragraph ID="ID607">Metoclopramide may cause a potentially fatal symptom complex called neuroleptic malignant syndrome (NMS). NMS has been reported in association with metoclopramide overdosage and concomitant treatment with another drug associated with NMS. Avoid metoclopramide tablets in patients receiving other drugs associated with NMS, including typical and atypical antipsychotics.</paragraph>
                        <paragraph>Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and manifestations of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac arrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Patients with such symptoms should be evaluated immediately.</paragraph>
                        <paragraph>In the diagnostic evaluation, consider the presence of other serious medical conditions (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms. Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology.</paragraph>
                        <paragraph>Management of NMS includes:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Immediate discontinuation of metoclopramide tablets and other drugs not essential to concurrent therapy
  
   <content styleCode="italics">[see Drug Interactions (
   
    <linkHtml href="#ID625">7.1</linkHtml>)]
  
   </content>.
 
  </item>
                           <item>Intensive symptomatic treatment and medical monitoring.</item>
                           <item>Treatment of any concomitant serious medical problems for which specific treatments are available.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID609">
                     <id root="348f148b-3e2a-fe2d-e063-6294a90a9b22"/>
                     <title>5.4 Depression</title>
                     <text>
                        <paragraph ID="ID610">Depression has occurred in metoclopramide-treated patients with and without a history of depression. Symptoms have included suicidal ideation and suicide. Avoid metoclopramide tablets use in patients with a history of depression.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID611">
                     <id root="348f148b-3e2b-fe2d-e063-6294a90a9b22"/>
                     <title>5.5 Hypertension</title>
                     <text>
                        <paragraph ID="ID612">Metoclopramide may elevate blood pressure. In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#ID625">7.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>There are also clinical reports of hypertensive crises in patients with undiagnosed pheochromocytoma. Metoclopramide tablets is contraindicated in patients with pheochromocytoma or other catecholamine-releasing paragangliomas
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#ID567">4</linkHtml>)].
 
  </content>Discontinue metoclopramide tablets in any patient with a rapid rise in blood pressure.

 </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID613">
                     <id root="348f148b-3e2c-fe2d-e063-6294a90a9b22"/>
                     <title>5.6 Fluid Retention</title>
                     <text>
                        <paragraph ID="ID614">Because metoclopramide tablets produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. Discontinue metoclopramide tablets if any of these adverse reactions occur.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID615">
                     <id root="348f148b-3e2d-fe2d-e063-6294a90a9b22"/>
                     <title>5.7 Hyperprolactinemia</title>
                     <text>
                        <paragraph ID="ID616">As with other dopamine D
 
  <sub>2</sub>receptor antagonists, metoclopramide elevates prolactin levels.

 </paragraph>
                        <paragraph>Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating drugs, including metoclopramide.</paragraph>
                        <paragraph>Hyperprolactinemia may potentially stimulate prolactin-dependent breast cancer. However, some clinical studies and epidemiology studies have not shown an association between administration of dopamine D
 
  <sub>2</sub>receptor antagonists and tumorigenesis in humans
 
  <content styleCode="italics">[see Nonclinical Toxicology (
  
   <linkHtml href="#ID667">13.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
               <component>
                  <section ID="ID617">
                     <id root="348f148b-3e2e-fe2d-e063-6294a90a9b22"/>
                     <title>5.8 Effects on the Ability to Drive and Operate Machinery</title>
                     <text>
                        <paragraph ID="ID618">Metoclopramide may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. Concomitant use of central nervous system (CNS) depressants or drugs associated with EPS may increase this effect (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics). Avoid metoclopramide tablets or the interacting drug, depending on the importance of the drug to the patient
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#ID625">7.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID573">
               <id root="348f148b-3e2f-fe2d-e063-6294a90a9b22"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Most common adverse reactions (&gt; 10%) are restlessness, drowsiness, fatigue, and lassitude. (
  
     <linkHtml href="#ID573">6</linkHtml>)
 
    </item>
                        </list>
                        <paragraph ID="ID576">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceutical, Inc., at 1-855-724-3436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID619">
                     <id root="348f148b-3e30-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID620">The following adverse reactions are described, or described in greater detail, in other sections of the labeling:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tardive dyskinesia
  
   <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (
   
    <linkHtml href="#ID601">5.1</linkHtml>)]
  
   </content>
                           </item>
                           <item>Other extrapyramidal effects
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID603">5.2</linkHtml>)]
  
   </content>
                           </item>
                           <item>Neuroleptic malignant syndrome
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID606">5.3</linkHtml>)]
  
   </content>
                           </item>
                           <item>Depression
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID609">5.4</linkHtml>)]
  
   </content>
                           </item>
                           <item>Hypertension
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID611">5.5</linkHtml>)]
  
   </content>
                           </item>
                           <item>Fluid retention
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID613">5.6</linkHtml>)]
  
   </content>
                           </item>
                           <item>Hyperprolactinemia
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID615">5.7</linkHtml>)]
  
   </content>
                           </item>
                           <item>Effects on the ability to drive and operate machinery
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID617">5.8</linkHtml>)]
  
   </content>
                           </item>
                        </list>
                        <paragraph ID="ID622">The following adverse reactions have been identified from clinical studies or postmarketing reports of metoclopramide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>The most common adverse reactions (in approximately 10% of patients receiving 10 mg of metoclopramide four times daily) were restlessness, drowsiness, fatigue, and lassitude. In general, the incidence of adverse reactions correlated with the dosage and duration of metoclopramide administration.</paragraph>
                        <paragraph>Adverse reactions, especially those involving the nervous system, occurred after stopping metoclopramide including dizziness, nervousness, and headaches.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Central Nervous System Disorders</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tardive dyskinesia, acute dystonic reactions, drug-induced parkinsonism, akathisia, and other extrapyramidal symptoms</item>
                           <item>Convulsive seizures</item>
                           <item>Hallucinations</item>
                           <item>Restlessness, drowsiness, fatigue, and lassitude occurred in approximately 10% of patients who received 10 mg four times daily. Insomnia, headache, confusion, dizziness, or depression with suicidal ideation occurred less frequently.</item>
                           <item>Neuroleptic malignant syndrome, serotonin syndrome (in combination with serotonergic agents).</item>
                        </list>
                        <paragraph ID="ID624">
                           <content styleCode="underline">Endocrine Disorders</content>: Fluid retention secondary to transient elevation of aldosterone. Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiovascular Disorders</content>: Acute congestive heart failure, possible atrioventricular block, hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal Disorders</content>: Nausea, bowel disturbances (primarily diarrhea)

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatic Disorders</content>: Hepatotoxicity, characterized by, e.g., jaundice and altered liver function tests, when metoclopramide was administered with other drugs with known hepatotoxic potential

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal and Urinary Disorders</content>: Urinary frequency, urinary incontinence

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hematologic Disorders</content>: Agranulocytosis, neutropenia, leukopenia, methemoglobinemia, sulfhemoglobinemia

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>: Bronchospasm (especially in patients with a history of asthma), urticaria; rash; angioedema, including glossal or laryngeal edema

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Eye Disorders</content>: Visual disturbances

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism Disorders</content>: Porphyria

 </paragraph>
                     </text>
                     <effectiveTime value="20250213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID577">
               <id root="348f148b-3e31-fe2d-e063-6294a90a9b22"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250313"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Antipsychotics</content>: Potential for additive effects, including TD, EPS, and NMS; avoid concomitant use. (
  
     <linkHtml href="#ID625">7.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">CNS depressants</content>: Increased risk of CNS depression. Avoid concomitant use and monitor for adverse reactions. (
  
     <linkHtml href="#ID625">7.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine)</content>: See Full Prescribing Information for recommended dosage reductions. (
  
     <linkHtml href="#ID589">2.2</linkHtml>,
  
     <linkHtml href="#ID592">2.3</linkHtml>,
  
     <linkHtml href="#ID625">7.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">MAO inhibitors</content>: Increased risk of hypertension; avoid concomitant use. (
  
     <linkHtml href="#ID611">5.5</linkHtml>,
  
     <linkHtml href="#ID625">7.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Additional drug interactions</content>: See Full Prescribing Information. (
  
     <linkHtml href="#ID625">7.1</linkHtml>,
  
     <linkHtml href="#ID628">7.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID625">
                     <id root="348f148b-3e32-fe2d-e063-6294a90a9b22"/>
                     <title>7.1 Effects of Other Drugs on Metoclopramide</title>
                     <text>
                        <paragraph ID="ID626">Table 3 displays the effects of other drugs on metoclopramide.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3. Effects of Other Drugs on Metoclopramide</content>
                        </paragraph>
                        <table ID="ID718" width="677">
                           <col width="151"/>
                           <col width="526"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Antipsychotics</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Potential for additive effects, including increased frequency and severity of tardive dyskinesia (TD), other extrapyramidal symptoms (EPS), and neuroleptic malignant syndrome (NMS).</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Avoid concomitant use
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#ID601">5.1</linkHtml>,
     
      <linkHtml href="#ID603">5.2</linkHtml>,
     
      <linkHtml href="#ID606">5.3</linkHtml>)].
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Strong CYP2D6 Inhibitors, not Included in Antipsychotic Category Above</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Increased plasma concentrations of metoclopramide; risk of exacerbation of extrapyramidal symptoms
    
     <content styleCode="italics">[see Clinical Pharmacology (
     
      <linkHtml href="#ID663">12.3</linkHtml>)].
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Reduce the metoclopramide tablets dosage
    
     <content styleCode="italics">[see Dosage and Administration (
     
      <linkHtml href="#ID589">2.2</linkHtml>,
     
      <linkHtml href="#ID592">2.3</linkHtml>)].
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">quinidine, bupropion, fluoxetine, and paroxetine</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Monoamine Oxidase Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Increased risk of hypertension
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#ID611">5.5</linkHtml>)].
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Avoid concomitant use.</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Central Nervous System (CNS) Depressants</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Increased risk of CNS depression
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#ID617">5.8</linkHtml>)].
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Avoid metoclopramide tablets or the interacting drug, depending on the importance of the drug to the patient.</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">alcohol, sedatives, hypnotics, opiates and anxiolytics</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Drugs that Impair Gastrointestinal Motility</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Decreased systemic absorption of metoclopramide.</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Monitor for reduced therapeutic effect.</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">antiperistaltic antidiarrheal drugs, anticholinergic drugs, and opiates</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Dopaminergic Agonists and Other Drugs that Increase Dopamine Concentrations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Decreased therapeutic effect of metoclopramide due to opposing effects on dopamine.</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">Monitor for reduced therapeutic effect.</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td align="left" styleCode="Botrule Rrule">apomorphine, bromocriptine, cabergoline, levodopa, pramipexole, ropinirole, and rotigotine</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID628">
                     <id root="348f148b-3e33-fe2d-e063-6294a90a9b22"/>
                     <title>7.2 Effects of Metoclopramide on Other Drugs</title>
                     <text>
                        <paragraph ID="ID689">Table 4 displays the effects of metoclopramide on other drugs.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 4. Effects of Metoclopramide on Other Drugs</content>
                        </paragraph>
                        <table ID="ID719" width="677" styleCode="Noautorules">
                           <col width="151"/>
                           <col width="526"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2">
                                    <paragraph styleCode="Footnote">* Interaction does not apply to posaconazole delayed-release tablets</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Toprule Botrule Rrule">
                                    <content styleCode="bold">Dopaminergic Agonists and Drugs Increasing Dopamine Concentrations</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                    <br/>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Opposing effects of metoclopramide and the interacting drug on dopamine. Potential exacerbation of symptoms (e.g., parkinsonian symptoms). 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Avoid concomitant use
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#ID603">5.2</linkHtml>)]
    
     </content>. 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Apomorphine, bromocriptine, cabergoline, levodopa, pramipexole, ropinirole, rotigotine 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="bold">Succinylcholine, Mivacurium</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Metoclopramide inhibits plasma cholinesterase leading to enhanced neuromuscular blockade. 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Monitor for signs and symptoms of prolonged neuromuscular blockade 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="bold">Drugs with Absorption Altered due to Increased Gastrointestinal Motility</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">The effect of metoclopramide on other drugs is variable. Increased gastrointestinal (GI) motility by metoclopramide may impact absorption of other drugs leading to decreased or increased drug exposure. 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">
                                    <content styleCode="underline">Drugs with Decreased Absorption (e.g., digoxin, atovaquone, posaconazole oral suspension*, fosfomycin)</content>: Monitor for reduced therapeutic effect of the interacting drug. For digoxin monitor therapeutic drug concentrations and increase the digoxin dose as needed (see prescribing information for digoxin). 
     <br/>
                                    <content styleCode="underline">Drugs with Increased Absorption (e.g., sirolimus, tacrolimus, cyclosporine)</content>: Monitor therapeutic drug concentrations and adjust the dose as needed. See prescribing information for the interacting drug. 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="bold">Insulin</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Botrule Rrule">
                                    <content styleCode="italics">Intervention</content>
                                    <br/>
                                 </td>
                                 <td align="left" styleCode=" Botrule Rrule">Monitor blood glucose and adjust insulin dosage regimen as needed. 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250109"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID630">
               <id root="348f148b-3e34-fe2d-e063-6294a90a9b22"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250313"/>
               <component>
                  <section ID="ID631">
                     <id root="348f148b-3e35-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID632">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Published studies, including retrospective cohort studies, national registry studies, and meta-analyses, do not report an increased risk of adverse pregnancy-related outcomes with use of metoclopramide during pregnancy.</paragraph>
                        <paragraph>There are potential risks to the neonate following exposure
 
  <content styleCode="italics">in utero</content>to metoclopramide during delivery
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID720">Clinical Considerations</linkHtml>].
 
  </content>In animal reproduction studies, no adverse developmental effects were observed with oral administration of metoclopramide to pregnant rats and rabbits at exposures about 6 and 12 times the maximum recommended human dose (MRHD)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID721">Data</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph ID="ID720">
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Metoclopramide crosses the placental barrier and may cause extrapyramidal signs and methemoglobinemia in neonates with maternal administration during delivery. Monitor neonates for extrapyramidal signs
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>,
  
   <linkHtml href="#ID603">5.2</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#ID635">8.4</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph ID="ID721">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproduction studies have been performed following administration of oral metoclopramide during organogenesis in pregnant rats at about 6 times the MRHD calculated on body surface area and in pregnant rabbits at about 12 times the MRHD calculated on body surface area. No evidence of adverse developmental effects due to metoclopramide were observed.</paragraph>
                     </text>
                     <effectiveTime value="20250212"/>
                  </section>
               </component>
               <component>
                  <section ID="ID633">
                     <id root="348f148b-3e36-fe2d-e063-6294a90a9b22"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID634">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited published data report the presence of metoclopramide in human milk in variable amounts. Breastfed infants exposed to metoclopramide have experienced gastrointestinal adverse reactions, including intestinal discomfort and increased intestinal gas formation
 
  <content styleCode="italics">[see Data]</content>. Metoclopramide elevates prolactin levels
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID615">5.7</linkHtml>)]
 
  </content>; however, the published data are not adequate to support drug effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metoclopramide tablets and any potential adverse effects on the breastfed child from metoclopramide tablets or from the underlying maternal condition.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Monitor breastfeeding neonates because metoclopramide may cause extrapyramidal signs (dystonias) and methemoglobinemia
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>,
  
   <linkHtml href="#ID603">5.2</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#ID635">8.4</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>In published clinical studies, the estimated amount of metoclopramide received by the breastfed infant was less than 10% of the maternal weight-adjusted dose. In one study, the estimated daily amount of metoclopramide received by infants from breast milk ranged from 6 to 24 mcg/kg/day in early puerperium (3 to 9 days postpartum) and from 1 to 13 mcg/kg/day at 8 to 12 weeks postpartum.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID635">
                     <id root="348f148b-3e37-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID636">Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. The safety and effectiveness of metoclopramide tablets in pediatric patients have not been established.</paragraph>
                        <paragraph>Dystonias and other extrapyramidal symptoms associated with metoclopramide are more common in pediatric patients than in adults
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>,
  
   <linkHtml href="#ID603">5.2</linkHtml>)]
 
  </content>. In addition, neonates have reduced levels of NADH-cytochrome b
 
  <sub>5</sub>reductase, making them more susceptible to methemoglobinemia, a possible adverse reaction of metoclopramide use in neonates
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID643">8.8</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID637">
                     <id root="348f148b-3e38-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID638">Metoclopramide is known to be substantially excreted by the kidney, and the risk of adverse reactions, including tardive dyskinesia (TD), may be greater in patients with impaired renal function
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID639">8.6</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#ID663">12.3</linkHtml>)]
 
  </content>. Elderly patients are more likely to have decreased renal function and may be more sensitive to the therapeutic or adverse effects of metoclopramide; therefore, consider a reduced dosage of metoclopramide tablets in elderly patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID543">Boxed Warning</linkHtml>, Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>), Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID639">
                     <id root="348f148b-3e39-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID640">The clearance of metoclopramide is decreased and the systemic exposure is increased in patients with moderate to severe renal impairment compared to patients with normal renal function, which may increase the risk of adverse reactions. Reduce the metoclopramide tablets dosage in patients with moderate and severe renal impairment (creatinine clearance less than or equal to 60 mL/minute), including those receiving hemodialysis and continuous ambulatory peritoneal dialysis
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#ID663">12.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID641">
                     <id root="348f148b-3e3a-fe2d-e063-6294a90a9b22"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID642">Patients with severe hepatic impairment (Child-Pugh C) have reduced systemic metoclopramide clearance (by approximately 50%) compared to patients with normal hepatic function. The resulting increase in metoclopramide blood concentrations increases the risk of adverse reactions. There is no pharmacokinetic data in patients with moderate hepatic impairment (Child-Pugh B). Reduce metoclopramide tablets dosage in patients with moderate or severe (Child-Pugh B or C) hepatic impairment
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>)]
 
  </content>. There is no dosage adjustment required for patients with mild hepatic impairment (Child-Pugh A).

 </paragraph>
                        <paragraph>In addition, metoclopramide, by producing a transient increase in plasma aldosterone, may increase the risk of fluid retention in patients with hepatic impairment
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID613">5.6</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Monitor patients with hepatic impairment for the occurrence of fluid retention and volume overload.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID643">
                     <id root="348f148b-3e3b-fe2d-e063-6294a90a9b22"/>
                     <title>8.8 NADH-Cytochrome b

 <sub>5</sub>Reductase Deficiency
</title>
                     <text>
                        <paragraph ID="ID644">Metoclopramide-treated patients with NADH-cytochrome b
 
  <sub>5</sub>reductase deficiency are at an increased risk of developing methemoglobinemia and/or sulfhemoglobinemia. For patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency with metoclopramide-induced methemoglobinemia, methylene blue treatment is not recommended. Methylene blue may cause hemolytic anemia in patients with G6PD deficiency, which may be fatal
 
  <content styleCode="italics">[see Overdosage (
  
   <linkHtml href="#ID647">10</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250212"/>
                  </section>
               </component>
               <component>
                  <section ID="ID645">
                     <id root="348f148b-3e3c-fe2d-e063-6294a90a9b22"/>
                     <title>8.9 CYP2D6 Poor Metabolizers</title>
                     <text>
                        <paragraph ID="ID646">Metoclopramide is a substrate of CYP2D6. The elimination of metoclopramide may be slowed in patients who are CYP2D6 poor metabolizers (compared to patients who are CYP2D6 intermediate, extensive, or ultra-rapid metabolizers); possibly increasing the risk of dystonic and other adverse reactions to metoclopramide tablets 
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#ID663">12.3</linkHtml>)].
 
  </content>Reduce the metoclopramide tablets dosage in patients who are poor CYP2D6 metabolizers
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID647">
               <id root="348f148b-3e3d-fe2d-e063-6294a90a9b22"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20250313"/>
               <component>
                  <section ID="ID648">
                     <id root="348f148b-3e3e-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID649">Manifestations of metoclopramide overdosage included drowsiness, disorientation, extrapyramidal reactions, other adverse reactions associated with metoclopramide use (including, e.g., methemoglobinemia), and sometimes death. Neuroleptic malignant syndrome (NMS) has been reported in association with metoclopramide overdose and concomitant treatment with another drug associated with NMS
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID601">5.1</linkHtml>,
  
   <linkHtml href="#ID603">5.2</linkHtml>,
  
   <linkHtml href="#ID606">5.3</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>There are no specific antidotes for metoclopramide tablets overdosage.</paragraph>
                        <paragraph>If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage
 
  <content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Methemoglobinemia can be reversed by the intravenous administration of methylene blue. However, methylene blue may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which may be fatal.</paragraph>
                        <paragraph>Hemodialysis and continuous ambulatory peritoneal dialysis do not remove significant amounts of metoclopramide.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID650">
               <id root="348f148b-3e3f-fe2d-e063-6294a90a9b22"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="ID651">
                     <id root="348f148b-3e40-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID652">Metoclopramide hydrochloride, the active ingredient of metoclopramide tablets, is a dopamine-2 receptor antagonist. Metoclopramide hydrochloride (metoclopramide monohydrochloride monohydrate) is a white crystalline, odorless substance, freely soluble in water. Its chemical name is 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy benzamide monohydrochloride monohydrate.</paragraph>
                        <paragraph>The molecular formula is C
 
  <sub>14</sub>H
 
  <sub>22</sub>ClN
 
  <sub>3</sub>O
 
  <sub>2</sub>•HCl•H
 
  <sub>2</sub>O. Its molecular weight is 354.28. The structural formula is:  

 </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="L4189bf72-c2be-4455-b536-1ac2765a367e"/>
                        </paragraph>
                        <paragraph ID="ID655">Metoclopramide tablets are for oral administration. Metoclopramide tablets are available as 5 mg and 10 mg tablets.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Each metoclopramide 5 mg tablet contains 5 mg metoclopramide (equivalent to 5.909 mg of metoclopramide hydrochloride USP). Inactive ingredients consist of microcrystalline cellulose, lactose monohydrate and magnesium stearate.</item>
                           <item>Each metoclopramide 10 mg tablet contains 10 mg metoclopramide (equivalent to 11.818 mg metoclopramide hydrochloride USP). Inactive ingredients consist of microcrystalline cellulose, lactose monohydrate and magnesium stearate.</item>
                        </list>
                        <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                     <component>
                        <observationMedia ID="L4189bf72-c2be-4455-b536-1ac2765a367e">
                           <text>metoclopramide structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="metoclopramide-structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID657">
               <id root="348f148b-3e41-fe2d-e063-6294a90a9b22"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250313"/>
               <component>
                  <section ID="ID659">
                     <id root="348f148b-3e42-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID660">Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs.</paragraph>
                        <paragraph>Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID661">
                     <id root="348f148b-3e43-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID662">
                           <content styleCode="underline">Gastroesophageal Reflux</content>
                        </paragraph>
                        <paragraph>In patients with gastroesophageal reflux and low lower esophageal sphincter pressure (LESP), single oral doses of metoclopramide tablet produced dose-related increases in LESP. Effects began at about 5 mg and increased through 20 mg. The increase in LESP from a 5 mg dose lasted about 45 minutes and that of 20 mg lasted between 2 and 3 hours. Increased rate of stomach emptying was observed with single oral doses of 10 mg.</paragraph>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
               <component>
                  <section ID="ID663">
                     <id root="348f148b-3e44-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID664">
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Relative to an intravenous dose of 20 mg, the absolute bioavailability of oral metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects. Peak plasma concentrations occurred at about 1 to 2 hours after a single oral dose. Similar time to peak was observed after individual doses at steady state.</paragraph>
                        <paragraph>In a single dose study of 12 subjects, the area under the drug concentration-time curve increased linearly with doses from 20 to 100 mg (5 times the maximum recommended single dose). Peak concentrations increased linearly with dose; time to peak concentrations remained the same; whole body clearance was unchanged; and the elimination rate remained the same. The mean elimination half-life in subjects with normal renal function was 5 to 6 hours. Linear kinetic processes adequately describe the absorption and elimination of metoclopramide.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Metoclopramide is not extensively bound to plasma proteins (about 30%). The whole body volume of distribution is high (about 3.5 L/kg), which suggests extensive distribution of drug to the tissues.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism: </content>Metoclopramide undergoes enzymatic metabolism via oxidation as well as glucuronide and sulfate conjugation reactions in the liver. Monodeethylmetoclopramide, a major oxidative metabolite, is formed primarily by CYP2D6, an enzyme subject to genetic variability
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#ID645">8.9</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion:</content>Approximately 85% of the radioactivity of an orally administered dose appeared in the urine within 72 hours. After oral administration of 10 or 20 mg, a mean of 18% and 22% of the dose, respectively, was recovered as free metoclopramide in urine within 36 hours.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment:</content>In a study of 24 patients with varying degrees of renal impairment (moderate, severe, and end-stage renal disease (ESRD) requiring dialysis), the systemic exposure (AUC) of metoclopramide in patients with moderate to severe renal impairment was about 2-fold the AUC in subjects with normal renal function. The AUC of metoclopramide in patients with ESRD on dialysis was about 3.5-fold the AUC in subjects with normal renal function
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>) and Use in Specific Populations (
  
   <linkHtml href="#ID639">8.6</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment:</content>In a group of 8 patients with severe hepatic impairment (Child- Pugh C), the average metoclopramide clearance was reduced by approximately 50% compared to patients with normal hepatic function
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID589">2.2</linkHtml>,
  
   <linkHtml href="#ID592">2.3</linkHtml>) and Use in Specific Populations (
  
   <linkHtml href="#ID641">8.7</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Metoclopramide on CYP2D6 Substrates</content>
                        </paragraph>
                        <paragraph>Although
 
  <content styleCode="italics">in vitro</content>studies suggest that metoclopramide can inhibit CYP2D6, metoclopramide is unlikely to interact with CYP2D6 substrates
 
  <content styleCode="italics">in vivo</content>at therapeutically relevant concentrations.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of CYP2D6 Inhibitors on Metoclopramide</content>
                        </paragraph>
                        <paragraph>In healthy subjects, 20 mg of metoclopramide and 60 mg of fluoxetine (a strong CYP2D6 inhibitor) were administered, following prior exposure to 60 mg fluoxetine orally for 8 days. The patients who received concomitant metoclopramide and fluoxetine had a 40% and 90% increase in metoclopramide C
 
  <sub>max</sub>and AUC
 
  <sub>0-∞</sub>, respectively, compared to patients who received metoclopramide alone (see Table 5)
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#ID625">7.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <table ID="ID665" width="101%">
                           <caption>Table 5. Metoclopramide Pharmacokinetic Parameters in Healthy Subjects with and without Fluoxetine</caption>
                           <col width="25%"/>
                           <col width="45%"/>
                           <col width="31%"/>
                           <tbody>
                              <tr>
                                 <td align="justify" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Parameter</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Metoclopramide </content>
                                    <content styleCode="bold">alone</content>
                                    <content styleCode="bold">(mean ± SD)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Metoclopramide </content>
                                    <content styleCode="bold">with </content>
                                    <content styleCode="bold">fluoxetine</content>
                                    <content styleCode="bold">(mean ± SD)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Botrule Lrule Rrule Toprule" valign="middle">C
    
     <sub>m</sub>
                                    <sub>a</sub>
                                    <sub>x</sub> (ng/mL) 
   
    </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">44 ±15</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">62.7 ± 9.2</td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Botrule Lrule Rrule Toprule" valign="middle">AUC
    
     <sub>0</sub>
                                    <sub>-</sub>
                                    <sub>∞</sub> (ngˑh/mL) 
   
    </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">313 ± 113</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">591 ± 140</td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Botrule Lrule Rrule Toprule" valign="middle">t
    
     <sub>1</sub>
                                    <sub>/</sub>
                                    <sub>2</sub> (h) 
   
    </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">5.5 ± 1.1</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">8.5 ± 2.2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250313"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID666">
               <id root="348f148b-3e45-fe2d-e063-6294a90a9b22"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250213"/>
               <component>
                  <section ID="ID667">
                     <id root="348f148b-3e46-fe2d-e063-6294a90a9b22"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID668">
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>A 77-week study was conducted in rats with oral metoclopramide doses up to 40 mg/kg/day (about six times the maximum recommended human dose on body surface area basis). Metoclopramide elevated prolactin levels and the elevation persisted during chronic administration. An increase in mammary neoplasms was found in rodents after chronic administration of metoclopramide
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID615">5.7</linkHtml>)].
 
  </content>In a rat model for assessing the tumor promotion potential, a 2-week oral treatment with metoclopramide at a dose of 260 mg/kg/day (about 35 times the maximum recommended human dose based on body surface area) enhanced the tumorigenic effect of N-nitrosodiethylamine.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Metoclopramide was positive in the
 
  <content styleCode="italics">in vitro</content>Chinese hamster lung cell/HGPRT forward mutation assay for mutagenic effects and in the
 
  <content styleCode="italics">in vitro</content>human lymphocyte chromosome aberration assay for clastogenic effects. It was negative in the
 
  <content styleCode="italics">in vitro</content>Ames mutation assay, the
 
  <content styleCode="italics">in vitro</content>unscheduled DNA synthesis assay with rat and human hepatocytes, and the
 
  <content styleCode="italics">in vivo</content>rat micronucleus assay.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Metoclopramide at intramuscular doses up to 20 mg/kg/day (about three times the maximum recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.</paragraph>
                     </text>
                     <effectiveTime value="20250213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID669">
               <id root="348f148b-3e47-fe2d-e063-6294a90a9b22"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250220"/>
               <component>
                  <section ID="ID670">
                     <id root="348f148b-3e48-fe2d-e063-6294a90a9b22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID671">White, round, biconvex tablet contains 5 mg of metoclopramide. The tablet is debossed with “345” on one side and plain on the other side. Available in bottles of 100 tablets (NDC 50228-232-01) and 500 tablets (50228-232-05).</paragraph>
                        <paragraph>White, round, biconvex tablets contains 10 mg of metoclopramide, debossed with “346” on one side and plain with a white bisect on the other side. Available in bottles of 100 tablets (NDC 50228-233-01), bottles of 500 (50228-233-05) tablets and 1000 tablets (NDC 50228-233-10).</paragraph>
                        <paragraph>Dispense tablets in tight, light-resistant container. Store tablets at controlled room temperature between 20°C and 25°C (68°F and 77°F).</paragraph>
                     </text>
                     <effectiveTime value="20250220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID696">
               <id root="348f148b-3e49-fe2d-e063-6294a90a9b22"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID691">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>Inform patients or their caregivers that metoclopramide tablets can cause serious adverse reactions. Instruct patients to discontinue metoclopramide tablets and contact a healthcare provider immediately if the following serious reactions occur:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Tardive dyskinesia and other extrapyramidal reactions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID601">5.1</linkHtml>,
   
    <linkHtml href="#ID603">5.2</linkHtml>)]
  
   </content>
                     </item>
                     <item>Neuroleptic malignant syndrome
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID606">5.3</linkHtml>)]
  
   </content>
                     </item>
                     <item>Depression and/or possible suicidal ideation
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID609">5.4</linkHtml>)]
  
   </content>
                     </item>
                  </list>
                  <paragraph ID="ID693">Inform patients or their caregivers that concomitant treatment with numerous other medications can precipitate or worsen serious adverse reactions such as tardive dyskinesia or other extrapyramidal reactions, neuroleptic malignant syndrome, and CNS depression
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#ID625">7.1</linkHtml>,
  
   <linkHtml href="#ID628">7.2</linkHtml>)]
 
  </content>. Explain that the prescriber of any other medication must be made aware that the patient is taking metoclopramide tablets.

 </paragraph>
                  <paragraph>Inform patients or their caregivers that metoclopramide tablets can cause drowsiness or dizziness, or otherwise impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID617">5.8</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph ID="ID695">Dispense the Medication Guide at: 
  <br/>  https://sciegenpharm.com/medication-guide/
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>A&amp;Z Pharmaceutical Inc. 
  <br/>  180 Oser Ave. Suite 300 
  <br/>  Hauppauge, NY 11788

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>ScieGen Pharmaceuticals, Inc. 
  <br/>  Hauppauge, NY 11788

 </paragraph>
                  <paragraph>R0125</paragraph>
                  <paragraph>LB8095</paragraph>
               </text>
               <effectiveTime value="20250313"/>
            </section>
         </component>
         <component>
            <section ID="ID698">
               <id root="348f148b-3e4a-fe2d-e063-6294a90a9b22"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table ID="ID680" width="677px">
                     <col width="677"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Dispense the Medication Guide available at: 
       <br/>  https://sciegenpharm.com/medication-guide/
      </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"/>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                                 <br/>  Metoclopramide (MET-oh-KLOE-pra-mide) tablets, oral use
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">Read this Medication Guide before you start taking metoclopramide tablets and each time you get a refill. There may be new information. If you take another product that contains metoclopramide (such as metoclopramide injection, metoclopramide orally disintegrating tablets, or metoclopramide oral solution), you should read the Medication Guide that comes with that product. Some of the information may be different. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is the most important information I should know about</content>
                              <content styleCode="bold">metoclopramide tablets?</content>
                              <br/>
                              <content styleCode="bold">Metoclopramide tablets can cause serious side effects, including:</content>
                              <br/>
                              <content styleCode="bold">Tardive dyskinesia (abnormal muscle movements).</content>These movements happen mostly in the face muscles. You cannot control these movements. They may not go away even after stopping metoclopramide tablets. There is no treatment for tardive dyskinesia, but symptoms may decrease or go away over time after you stop taking metoclopramide tablets. 
     <br/>  Your chances for getting tardive dyskinesia increase: 
     <br/>
                              <list listType="unordered">
                                 <item>the longer you take metoclopramide tablets and the more metoclopramide tablets you take. You should not take metoclopramide tablets for more than 12 weeks.</item>
                                 <item>if you are older, especially if you are an older woman.</item>
                                 <item>if you have diabetes.</item>
                              </list>It is not possible for your healthcare provider to know if
    
     <content styleCode="bold">you</content>will get tardive dyskinesia if you take metoclopramide tablets. 
     <br/>  Call your healthcare provider right away if you get movements you cannot stop or control, such as: 
     <br/>
                              <list listType="unordered">
                                 <item>lip smacking, chewing, or puckering up your mouth</item>
                                 <item>frowning or scowling</item>
                                 <item>sticking out your tongue</item>
                                 <item>blinking and moving your eyes</item>
                                 <item>shaking of your arms and legs</item>
                              </list>See the section
    
     <content styleCode="bold">"What are the possible side effects of</content>
                              <content styleCode="bold">metoclopramide tablets?"</content>for more information about side effects.
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is </content>
                              <content styleCode="bold">metoclopramide tablets?</content>
                              <br/>  Metoclopramide tablets is a prescription medicine used in adults: 
     <br/>
                              <list listType="unordered">
                                 <item>for 4 to 12 weeks to relieve heartburn symptoms with gastroesophageal reflux when certain other treatments do not work.</item>
                                 <item>to relieve the symptoms of slow stomach emptying in people with diabetes.</item>
                              </list>Metoclopramide tablets are not recommended for use in children.
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Do not take</content>
                              <content styleCode="bold">metoclopramide tablets if you:</content>
                              <br/>
                              <list listType="unordered">
                                 <item>have a history of tardive dyskinesia or have a problem controlling your muscles and movements after taking metoclopramide tablets or a medicine that works like metoclopramide tablets.</item>
                                 <item>have stomach or intestine problems that could get worse with metoclopramide tablets, such as bleeding, blockage or a tear in the stomach or bowel wall.</item>
                                 <item>have a type of tumor that can cause high blood pressure such as pheochromocytoma.</item>
                                 <item>have epilepsy (seizures). Metoclopramide tablets can increase your chance for seizures and make them worse.</item>
                                 <item>are allergic to metoclopramide. Metoclopramide tablets can cause serious allergic reactions. Stop taking metoclopramide tablets right away and get emergency help if you have any of these symptoms:</item>
                              </list>            o swelling of your tongue, throat, lips, eyes or face. 
     <br/>              o trouble swallowing or breathing. 
     <br/>              o skin rash, hives, sores in your mouth, or skin blisters.
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking</content>
                                 <content styleCode="bold">metoclopramide tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <paragraph/>
                              <list listType="unordered">
                                 <item>have diabetes. Your dose of insulin may need to be changed.</item>
                                 <item>had problems controlling your muscle movements after taking any medicine.</item>
                                 <item>have Parkinson's disease.</item>
                                 <item>have a type of tumor that can cause high blood pressure (pheochromoctyoma).</item>
                                 <item>have kidney or liver disease.</item>
                                 <item>have or had depression or mental illness.</item>
                                 <item>have high blood pressure.</item>
                                 <item>have heart failure or heart rhythm problems.</item>
                                 <item>have breast cancer.</item>
                                 <item>drink alcohol.</item>
                                 <item>have seizures</item>
                                 <item>are pregnant or plan to become pregnant. Metoclopramide tablets may harm your unborn baby if taken during the end of pregnancy. Talk to your healthcare provider if you become pregnant while taking metoclopramide tablets.</item>
                                 <item>are breastfeeding or plan to breastfeed. Metoclopramide tablets can pass into your breast milk and may harm your baby. You and your healthcare provider should decide if you will take metoclopramide tablets or breastfeed.</item>
                              </list>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 
     <br/>  Metoclopramide tablets may affect the way other medicines work, and other medicines may affect how metoclopramide tablets works. 
     <br/>  Tell your healthcare provider before you start or stop other medicines.
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              <list listType="unordered">
                                 <item>another medicine that contains metoclopramide, such as metoclopramide injection or metoclopramide oral solution</item>
                                 <item>a medicine for Parkinson's disease</item>
                                 <item>a blood pressure medicine</item>
                                 <item>a medicine for depression, especially a Monoamine Oxidase Inhibitor (MAOI)</item>
                                 <item>an anti-psychotic medicine, used to treat mental illness such as schizophrenia</item>
                                 <item>insulin</item>
                                 <item>medicines that can make you sleepy, such as anti-anxiety medicines, sleep medicines, and narcotics</item>
                              </list>
                              <paragraph>If you are not sure if your medicine is one listed above, ask your healthcare provider or pharmacist.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>  Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
      </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I take</content>
                              <content styleCode="bold">metoclopramide tablets?</content>
                              <br/>
                              <list listType="unordered">
                                 <item>Take metoclopramide tablets exactly as your healthcare provider tells you. Do not change your dose unless your healthcare provider tells you to.</item>
                                 <item>Metoclopramide tablets come as a tablet you take by mouth.</item>
                                 <item>You should not take metoclopramide tablets for more than 12 weeks.</item>
                                 <item>Take metoclopramide tablets at least 30 minutes before each meal and at bedtime.</item>
                                 <item>If you take too much metoclopramide tablets, call your poison control center at 1-800-222-1222 or go to the nearest emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while taking</content>
                                 <content styleCode="bold">metoclopramide tablets?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Do not drink alcohol while taking metoclopramide tablets. Alcohol may make some side effects of metoclopramide tablets worse, such as feeling sleepy.</item>
                                 <item>Do not drive, operate machinery, or do other dangerous activities until you know how metoclopramide tablets affects you. Metoclopramide tablets may cause sleepiness or dizziness.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of</content>
                                 <content styleCode="bold">metoclopramide tablets?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Tardive dyskinesia (abnormal muscle movements).</content>See
      
       <content styleCode="bold">"What is the most important information I need to know about</content>
                                    <content styleCode="bold">metoclopramide tablets?"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Other changes in muscle control and movement, such as:</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Uncontrolled spasms of your face and neck muscles, or muscles of your body, arms, and legs (dystonia).</content>These muscle spasms can cause abnormal movements and body positions, and speech problems. These spasms usually start within the first 2 days of treatment. Rarely, these muscle spasms may cause trouble breathing. These spasms happen more often in adults less than 30 years of age.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Parkinsonism.</content>Symptoms include slight shaking, body stiffness, trouble moving or keeping your balance. If you already have Parkinson's Disease, your symptoms may become worse while you are taking metoclopramide tablets.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Being unable to sit still or feeling you need to move your hands, feet, or body (akathisia).</content>Symptoms can include feeling jittery, anxious, irritated or unable to sleep (insomnia), feeling the need to walk around (pacing) and tapping your feet.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Neuroleptic Malignant Syndrome (NMS).</content>NMS is a very rare but very serious condition that can happen with metoclopramide tablets. NMS can cause death and must be treated in a hospital. Symptoms of NMS include: high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased sweating.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Depression, thoughts about suicide, and suicide.</content>Some people who take metoclopramide tablets become depressed, even if they have no history of depression. You may have thoughts about hurting or killing yourself. Some people who have taken metoclopramide tablets have ended their own lives (suicide).
     
      </item>
                                 <item>
                                    <content styleCode="bold">High blood pressure.</content>metoclopramide tablets can cause your blood pressure to increase.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Too much body water.</content>People who have certain liver problems or heart failure and take metoclopramide tablets may hold too much water in their body (fluid retention). Tell your doctor right away if you have sudden weight gain, or swelling of your hands, legs, or feet.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Increased prolactin.</content>Tell your doctor if your menstrual periods stop, your breasts get larger and make milk, or you cannot have sex (impotence). These symptoms go away when you stop taking metoclopramide tablets.
     
      </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider and get medical help right away if you:</content>
                                 <br/>       • feel depressed or have thoughts about hurting or killing yourself 
      <br/>       • have high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased sweating 
      <br/>       • have muscle movements you cannot stop or control 
      <br/>       • have muscle movements that are new or unusual 
      <br/>  The most common side effects of metoclopramide tablets include: 
      <br/>       • restlessness 
      <br/>       • drowsiness 
      <br/>       • tiredness 
      <br/>       • lack of energy 
      <br/>  You may have more side effects the longer you take metoclopramide tablets and the more metoclopramide tablets you take. 
      <br/>  You may still have side effects after stopping metoclopramide tablets. You may have symptoms from stopping metoclopramide tablets such as headaches, and feeling dizzy or nervous. 
      <br/>   Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of metoclopramide tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store</content>
                                 <content styleCode="bold">metoclopramide tablets?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Store metoclopramide tablets at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Keep metoclopramide tablets in the bottle it comes in and away from light. Keep the bottle closed tightly.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep</content>
                                 <content styleCode="bold">metoclopramide tablets and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of</content>
                              <content styleCode="bold">metoclopramide tablets.</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use metoclopramide tablets for a condition for which it was not prescribed. Do not give metoclopramide tablets to other people, even if they have the same symptoms that you have. It may harm them. 
     <br/>  You can ask your pharmacist or healthcare provider for information about metoclopramide tablets that is written for health professionals.
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in</content>
                                 <content styleCode="bold">metoclopramide tablets?</content>
                                 <br/>
                                 <content styleCode="bold">Active ingredient:</content>metoclopramide 
      <br/>
                                 <content styleCode="bold">Inactive ingredients:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Metoclopramide Tablets USP, 5mg: microcrystalline cellulose, lactose monohydrate and magnesium stearate.</item>
                                 <item>Metoclopramide Tablets USP, 10mg: microcrystalline cellulose, lactose monohydrate and magnesium stearate.</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID712">
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>  A&amp;Z Pharmaceutical Inc. 
  <br/>  180 Oser Ave. Suite 300 
  <br/>  Hauppauge, NY 11788

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                     <br/>  ScieGen Pharmaceuticals, Inc. 
  <br/>  Hauppauge, NY 11788

 </paragraph>
                  <paragraph>For more information, call ScieGen Pharmaceuticals, Inc., at 1-855-724-3436.</paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>LB8095</paragraph>
                  <paragraph>R0125</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="L94baa4d5-4247-46be-91b2-15799d325ac5">
               <id root="348f148b-3e4b-fe2d-e063-6294a90a9b22"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">Metoclopramide Tablets USP 5 mg-Container Labels</content>
               </title>
               <text>
                  <paragraph>Each tablet contains Metoclopramide USP 5 mg (equivalent to 5.91 mg of metoclopramide hydrochloride USP)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                     <br/>  ScieGen Pharmaceuticals, Inc.

 </paragraph>
                  <paragraph>Hauppauge, NY 11788</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L651452a2-8db3-42dd-864d-9acc19fe4b27"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lfd39e2cf-70e3-4817-86a5-9d9cdabfbb01"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <observationMedia ID="L651452a2-8db3-42dd-864d-9acc19fe4b27">
                     <text>5mg-100s-label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="metoclopramide-5mg-100s-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lfd39e2cf-70e3-4817-86a5-9d9cdabfbb01">
                     <text>5mg-500s</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="5mg-500s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L96e2a51d-7018-4f07-8f1e-4f3f069c6cf8">
               <id root="348f148b-3e4c-fe2d-e063-6294a90a9b22"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">Metoclopramide Tablets USP 10 mg-Container Labels</content>
               </title>
               <text>
                  <paragraph>Each tablet contains Metoclopramide USP 10 mg (equivalent to 11.82 mg of metoclopramide hydrochloride USP)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                     <br/>  ScieGen Pharmaceuticals, Inc. 
  <br/>  Hauppauge, NY 11788

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L34aacbf1-c79e-492d-b609-20e0e5969872"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L1c61dab3-5567-44cb-b022-5845b648458b"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lc9bf15da-15ee-410c-80e3-756dca37d9fd"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <observationMedia ID="L34aacbf1-c79e-492d-b609-20e0e5969872">
                     <text>10mg-100s</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="10mg-100s-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L1c61dab3-5567-44cb-b022-5845b648458b">
                     <text>10mg-500s</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="10mg-500s-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lc9bf15da-15ee-410c-80e3-756dca37d9fd">
                     <text>10mg-1000s</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="10mg-1000s-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>